Nrx Pharmaceuticals Inc Stock Price, News & Analysis

NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, has rescheduled its second quarter 2025 financial results release to August 19, 2025 after market close. The company will host a conference call the following morning on August 20, 2025, at 8:00 AM ET.

The delay is due to the company requiring additional time to compile certain information and recent developments into their Form 10-Q filing. Investors can access the results via press release on the company's website and join the conference call through a webcast or by dialing +1-800-717-1738 (domestic) or +1-646-307-1865 (international).

NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, will release its Q2 2025 financial results on August 14, 2025, after market close.

The company will host a conference call at 4:30 PM ET to discuss corporate updates, financial performance, recent regulatory events, and operational plans. Investors can access the call via webcast on the company's website or by dialing +1-800-717-1738 (domestic) or +1-646-307-1865 (international).

NRx Pharmaceuticals (NASDAQ:NRXP) has received FDA Fast Track designation for NRX-100, its intravenous ketamine treatment for suicidal ideation in patients with depression, including bipolar depression. This expanded designation represents a 10-fold increase in the addressable population compared to its 2017 designation.

Clinical trials demonstrated significant efficacy, with 55% response rate in suicidal patients compared to 30% for active comparator, and 63% achieving full remission from suicidal ideation within three days versus 31% for placebo. The company targets a $3+ billion market opportunity, addressing approximately 13 million Americans who consider suicide annually.

NRX-100 is the first preservative-free ketamine formulation filed with FDA, offering potential three-year room temperature shelf life. The company has completed CMC information filing and is pursuing a Commissioner's National Priority Voucher to expedite review.

NRx Pharmaceuticals (NASDAQ:NRXP) announced that its subsidiary HOPE Therapeutics has received final clearance from Florida's Agency for Health Care Administration (AHCA) to proceed with the acquisition of Dura Medical. Dura Medical, founded in 2018, is a revenue-generating and EBITDA-positive healthcare provider specializing in precision psychiatry services on Florida's west coast.

The acquisition, along with previously announced purchases of Neurospa TMS and Cohen and Associates, will expand HOPE's presence in Florida. Dura Medical provides advanced treatments including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Spravato® for depression, PTSD, and related disorders. The company aims to treat over 10,000 patients by 2026 and serves both civilian and veteran patients through the Veterans Affairs Community Cares Network.

NRx Pharmaceuticals (NASDAQ:NRXP) has filed a Citizen Petition with the FDA requesting the removal of Benzethonium Chloride (BZT) from all ketamine products sold in the United States. The company emphasizes that BZT is a toxic preservative not recognized as safe by the FDA for parenteral products or topical use.

In June 2025, NRx filed an Abbreviated New Drug Application for a preservative-free ketamine preparation, demonstrating 3-year room temperature stability. The company has established US-based manufacturing and is pursuing approval for ketamine use in treating suicidal depression through FDA's National Priority Voucher Program.

This initiative aligns with federal priorities to eliminate toxic additives from the US drug supply and promote domestic pharmaceutical manufacturing.

NRx Pharmaceuticals (NASDAQ: NRXP) announced its participation in the BTIG Virtual Biotechnology Conference. CEO and Chairman Prof. Jonathan Javitt will participate in a fireside chat alongside Prof. Samuel Wilkinson from Yale School of Medicine and BTIG Research Analyst Dr. Thomas Shrader.

The discussion, scheduled for July 30, 2025, at 8:00 a.m. EDT, will focus on neuroplasticity in the treatment of CNS disorders. Prof. Wilkinson brings expertise in ketamine and neuroplastic/psychedelic drugs for treating depression, suicidality, and PTSD.

NRx Pharmaceuticals (NASDAQ:NRXP) announced that its subsidiary, HOPE Therapeutics, has signed a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, a premier interventional psychiatry clinic in western Florida.

Cohen and Associates, founded by Dr. Rebecca Cohen, will serve as a foundational clinic in the Sarasota-Bradenton region. The clinic specializes in treating suicidal depression, PTSD, and other CNS disorders through various treatments including ketamine, Spravato, and Transcranial Magnetic Stimulation (TMS). The acquisition is expected to be immediately accretive to revenue and EBITDA.

NRx Pharmaceuticals (NASDAQ:NRXP) has filed for the FDA's new Commissioner's National Priority Voucher (CNPV) program for NRX-100, its preservative-free ketamine formulation. The CNPV program could reduce FDA review time from 10-12 months to 1-2 months. The company's application aligns with all required criteria, including addressing the US health crisis of suicidal depression and PTSD. NRx has already submitted CMC information and received FDA feedback, maintaining its timeline for potential approval by end of 2025. The company is targeting the current $750 million ketamine market, projected to reach $3-5 billion by 2033. NRx is also filing a citizen petition to withdraw preservative-containing ketamine forms and has filed a patent for its preservative-free manufacturing process.

NRx Pharmaceuticals (NASDAQ: NRXP) and its subsidiary HOPE Therapeutics announced a strategic investor relations partnership with astr partners, a boutique IR firm specializing in life sciences. The partnership comes at a crucial time as NRx has filed an ANDA and is approaching completion of two NDA filings, while actively acquiring profitable interventional psychiatry clinics. astr partners, founded by former The Trout Group veterans Jonathan Fassberg and Brian Korb, will provide comprehensive IR services including investor targeting, message development, earnings preparation, and investor engagement. The firm brings extensive experience in biotech investor relations and healthcare capital markets, having previously held senior positions at Solebury Trout and Oppenheimer & Co.